modelAmisulpride

Diagram of Amisulpride

Extends from Pharmacolibrary.Drugs.ATC.N.N05AL05.

Information

name:Amisulpride
ATC code:N05AL05
route:oral
compartments:2
dosage:50mg
volume of distribution:6.4L
clearance:0.39L/h/kg
other parameters in model implementation

Amisulpride is an atypical antipsychotic medication primarily used to treat schizophrenia and, in some countries, depressive disorders. It acts mainly as a selective dopamine D2 and D3 receptor antagonist. Amisulpride is approved and marketed in several countries, but not in the United States.

Pharmacokinetics

Pharmacokinetics observed in healthy adult volunteers following oral administration.

References

  1. Cao, SS, et al., & Zhang, BK (2017). Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers
. International journal of clinical pharmacology and therapeutics 55(10) 825–831. DOI:10.5414/CP203000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28793958

  2. Hamon-Vilcot, B, et al., & Piette, F (1998). Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. European journal of clinical pharmacology 54(5) 405–409. DOI:10.1007/s002280050483 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9754984

  3. Täubel, J, et al., & Camm, AJ (2017). Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. British journal of clinical pharmacology 83(2) 339–348. DOI:10.1111/bcp.13128 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27618796

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)